Complexity and simplification in the development of nanomedicines

Nanomedicine

Volumn 10, Issue 20, 2015, Pages 3093-3097

  Barz, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

EPR; nanomedicine; SMART

Indexed keywords

NANOPARTICLE; POLYMER;

CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; NANOMEDICINE; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; ANIMAL; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; NANOMEDICINE; NANOPARTICLES;

EID: 84944243676     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.146     Document Type: Review

References (25)

1. Strebhardt K, Ullrich A. Paul Ehrlich's magical bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480 (2008).
2. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8(6), 2101-2141 (2011).
3. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9, 1-14 (2013).
4. Lammers T. SMART drug delivery systems: back to the future vs clinical reality. Int. J. Pharm. 454(1), 527-529 (2013).
5. Grainger DW. Connecting drug delivery reality to smart materials design. Int. J. Pharm. 454(1), 521-524 (2013).
6. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? Methods Mol. Biol. 525, i-xiii (2009).
7. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36-48 (2013).
8. Pelegri-O'Day EM, Lin EW, Maynard HD. Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J. Am. Chem. Soc. 136 (41), 14323-14332 (2014).
9. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable controlled release depots for large molecules. J. Control. Release 190, 240-253 (2014).
10. Talelli M, Barz M, Rijcken CJ, Kiessling F, Hennink WE, Lammers T. Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation. Nano Today 10 (1), 93-117 (2015).
11. Aharoni R. Immunomodulation neuroprotection and remyelination-the fundamental therapeutic effects of glatiramer acetate: a critical review. J. Autoimmun. 54, 81-92 (2014).
12. Hu Q, Rijcken CJ, Bansal R, Hennink WE, Storm G, Prakash J. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials 53, 370-378 (2015).
13. Barz M, Luxenhofer R, Zentel R, Vicent MJ. Defined polymers for therapeutic applications: from structureproperty relationships to better defined therapeutics. Polym. Chem. 2, 1900-1918 (2011).
14. Klinker K, Barz M. Polypept(o)ides-hybrid systems based on polypeptides and polypeptoids. Macromol. Rapid Commun. doi: 10.1002/marc.201500403 (2015) (Epub ahead of print).
15. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392 (1986).
16. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131-135 (2011).
17. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000).
18. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71, 409-419 (2009).
19. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 303(5665), 1818-1822 (2004).
20. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99, 392-397 (2008).
21. Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release 190, 465-476 (2014).
22. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc. Chem. Res. 44(10), 1029-1038 (2011).
23. Kunjachan S, Pola R, Gremse F et al. Passive versus active tumor targeting using RGD-and NGR-modified polymeric nanomedicines. Nano Lett. 14(2), 972-981 (2014).
24. Vachutinsky Y, Oba M, Miyata K et al. Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles. J. Control. Release 149(1), 51-57 (2011).
25. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad O. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014).